Publications
MS Health documents available to download or print.
MS Health makes a range of publications available to benefit and improve the Sexual and Reproductive Health sector through our bodies of work. We are committed to accountability, information sharing, and collaboration.
Browse the table below to access our Publications in PDF format. Documents include the MS Health 2021-2023 Strategic Plan, as well as Impact Reports, Prescriber and Dispenser updates, and more.
| Cover | Title | Date | Summary | Link | hf:doc_categories |
|---|---|---|---|---|---|
| Statement on changes to medical abortion accessibility | 28 July 2023 | This statement provides an update on the TGA and PBAC changes to the medical … | |||
 | Medical abortion prescriber and dispenser update (June 2023) | 25 July 2023 | Our risk management plan and the certification program play an important part in how we and our national regulator ensure medicines of this kind are safely and responsibly provided in Australia. The table below shows all actively certified dispensers and … | prescriber-and-dispenser-update | |
 | MS Health Strategic Plan 2021–2023 | 25 July 2023 | This Strategic Plan is an integral shift towards a new agenda, one of greater collaboration and action. Through this strategy, we not only want to empower agency for clients, but for all people within our collaborative partnerships. | strategic-plan | |
 | Impact Report 2022 | 23 June 2023 | In collaboration with key stakeholders, MS Health has lodged updated proposals to the Therapeutic Goods Administration (TGA) that will make medical abortion more accessible to women and pregnant people across Australia. | impact-report | |
| Medical abortion prescriber and dispenser update (December 2022) | 25 January 2023 | Our risk management plan and the certification program play an important part in how we and our national regulator ensure medicines of this kind are safely and responsibly provided in Australia. The table below shows all actively certified dispensers and … | prescriber-and-dispenser-update | |
 | Australian Product Information MS-2 Step (Mifepristone and Misoprostol) Tablets | 23 August 2022 | This document refers to the use of MS-2 Step, which consists of Mifepristone Linepharma 200mg tablet and GyMiso® misoprostol 200 microgram tablets in combination. These medicines are indicated in females of childbearing age for the medical termination of an intrauterine … | product-information | |
| Australian Product Information Mifepristone Linepharma (Mifepristone) 200mg Tablet | 10 August 2022 | This medication is only for use in termination of pregnancy for medical reasons beyond the first trimester. Medical termination of pregnancy up to 63 days gestation requires the use of MS-2 Step (mifepristone, misoprostol). This medication should only be prescribed … | product-information | |
| Medical abortion prescriber and dispenser update (July 2022) | 25 July 2022 | Our risk management plan and the certification program play an important part in how we and our national regulator ensure medicines of this kind are safely and responsibly provided in Australia. The table below shows all actively certified dispensers and … | prescriber-and-dispenser-update | |
| Medical abortion prescriber and dispenser update (December 2021) | 5 January 2022 | Our risk management plan and the certification program play an important part in how we and our national regulator ensure medicines of this kind are safely and responsibly provided in Australia. The table below shows all actively certified dispensers and … | prescriber-and-dispenser-update | |
 | MS Health Impact Report 2021 | 1 January 2022 | Our organisation has taken significant steps to maintain a stable supply chain during challenging times, ensuring the continued availability of medical abortion medication for those in need. | impact-report | |
| Consumer Medicine Information – Mifepristone Linepharma 200 mg | 8 July 2021 | This medication is for use in termination of pregnancy for medical reasons beyond the first trimester. For medical termination of pregnancy up to 63 days gestation, a different product should be used (MS-2 Step (mifepristone and misoprostol). It is important … | consumer-medicine-information | |
 | MS Health Impact Report 2020 | 1 January 2021 | Welcome to MS Health’s first ever Impact Report. The year posed a number of challenges to the organisation, from the pandemic itself as well as policies of containment here in Australia and abroad. These challenges have arguably forced many of … | impact-report | |
| Consumer Medicine Information – MS-2 Step Mifepristone Linepharma 200 mg Tablet Pack | 1 June 0202 | MS-2 Step Mifepristone Linepharma 200 mg Tablet Pack. Each tablet contains mifepristone 200 mg. Consumer Medicine Information. It is very important that all patients receiving this medication are followed up by a medical practitioner, preferably the prescriber, to ensure that … | consumer-medicine-information |
This page last edited: June 2023